PolyMedix Inc. Receives USAN Approval for Generic Name of Brilacidin for PMX-30063

Published: Jun 13, 2012

RADNOR, Pa., June 12, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "brilacidin" (pronounced bri-la-ci-din) for PMX-30063, a first-in-class defensin mimetic antibiotic. PolyMedix recently announced positive results from a Phase 2 clinical study with brilacidin as an intravenous treatment in patients with acute bacterial skin and skin structure Staph aureus infections.

Back to news